100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
logo-home
Pharm exam 2 notes $8.49   Add to cart

Class notes

Pharm exam 2 notes

 0 view  0 purchase

Class notes for exam 2

Preview 3 out of 26  pages

  • October 29, 2024
  • 26
  • 2023/2024
  • Class notes
  • Grier
  • All classes
All documents for this subject (4)
avatar-seller
madisonbarton00
Pharmacology Exam 2
Regulation of Blood Glucose Review
Glucose essential for cellular function

- Normal BG 70-120 mg/dl maintained by insulin and counter-regulatory hormones
Insulin from beta cells of pancreas opens cell to allow glucose entry

-Basal rate and bolus (with meals)
Counter-regulatory hormones released with low blood glucose levels

- Fast release of glucose
o Glucagon from alpha cells of pancreas
o Epinephrine from medulla of adrenal glands
- Slow release of glucose
o Cortisol from cortex of adrenal glands
o Growth hormone from anterior pituitary gland

Diagnostic Criteria for Diabetes
Fasting blood glucose > 126 mg/dL
HbA1c > 6.5%
HbA1c (%) Fasting blood glucose
6 126
8 183
10 240
12 298


Pharmacology Overview for Diabetes
Goals of interventions

- Control blood glucose
- Prevent complications
o Lifestyle modifications with pharmacologic therapy
Type 1 DM – no insulin
- Insulin
- Combination
o Long acting
o Rapid-acting
Type 2 DM – some insulin

- Oral agents
- Non-insulin injectable(s)

, - Insulin
o Long acting

o Rapid-acting


Class: Insulin
MOA: Replacement of endogenous insulin

- Promote cellular uptake of glucose, amino acids, potassium; protein synthesis, glycogen formation/storage,
fatty acid storage
Indication: T1DM, T2DM, DKA (regular insulin only), hyperkalemia
AE: Hypoglycemia; lipohypertrophy, lipodystrophy at injection site; diarrhea, hypokalemia


Insulin: Rapid Acting
Generic (Brand) Onset (min) Peak Duration (hours)
Lispro (Humalog) 5-15 min 30-60 min 3-4
Aspart (Novolog) 10-20 min 1-3 hours 3-5
Route: Subcutaneous injection
Dose: Up to 4 times daily (meals and HS)
Risk for hypoglycemia = peak action time


Nursing: Rapid Acting Insulin
Always check blood glucose prior to administration

-Prior to eating
Admin med 0-15 minutes prior to start of meal

- Rotate injection sites
Verify orders, follow facility protocol for admin

- Set dose (ex: 5 units with meal)
- Sliding scale (units to admin based on BG level; add to routine dose)
Hold parameters

- Do not give rapid insulin if BG less than ….. (check order)
- Consider NPO status
Insulin Delivery Devices
Insulin by syringe

- Widely used; inexpensive
- Multi-dose vial
o Keep unopened vials refrigerated; once open, room temp for 30 days
- Syringe one time use
Insulin by pen

- Pre-filled syringe
- Multi-dose syringe – disinfect with alcohol
- New needle attached for each use
- Prime pen first, then dial for dose
Infusion set insertion device

, - Cannula in SQ tissue and tubing
- Risk for infection at insertion site
Insulin reservoir
- Slow insulin release + bolus (rapid for short acting insulin)
Frequent BG monitoring

- Continuous glucose monitoring communicates with pump
Insulin Delivery Devices: Intravenous (IV) Insulin Drip
Indications:

- Diabetic ketoacidosis
- Hyperosmolar state
- Critical care
- Peri-operative period
- NPO type 1 diabetes
- Labor and delivery
- Glucose exacerbated by high dose glucocorticoid therapy
- TPN
Peripheral or central line

- Insulin on IV pump to deliver continuous drip of medication based on BG level
- BG checked hourly
- Standing orders
Non-insulin Agents: T2DM only
Mechanism of actions

- Increase insulin releasee
- Decreased glucagon release
- Slow GI absorption of glucose
- Block glucose reabsorption in the kidneys (excrete more glucose in urine)
May be used in combination or with insulin to achieve BG targets
Many new drugs being developed for treatment of T2DM


Class: Biguanides Prototype: metformin (Glucophage)
MOA: increases insulin sensitivity; decreases hepatic glucose production and decreases GI glucose absorption
Indications: T2DM
Route: Oral
AE: GI effects (n/v/d); lactic acidosis
Nursing: Low risk for hypoglycemia; hold 2 days prior and 2 days after IV contrast (risk AKI)


Class: Sulfonylureas, Second Generation Prototype: glipizide (Glucotrol)
MOA: increases insulin receptor sensitivity and increases insulin secretion; decreases hepatic production glucose
Route: Oral
Caution: Sulfa allergy

The benefits of buying summaries with Stuvia:

Guaranteed quality through customer reviews

Guaranteed quality through customer reviews

Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.

Quick and easy check-out

Quick and easy check-out

You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.

Focus on what matters

Focus on what matters

Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!

Frequently asked questions

What do I get when I buy this document?

You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.

Satisfaction guarantee: how does it work?

Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.

Who am I buying these notes from?

Stuvia is a marketplace, so you are not buying this document from us, but from seller madisonbarton00. Stuvia facilitates payment to the seller.

Will I be stuck with a subscription?

No, you only buy these notes for $8.49. You're not tied to anything after your purchase.

Can Stuvia be trusted?

4.6 stars on Google & Trustpilot (+1000 reviews)

80364 documents were sold in the last 30 days

Founded in 2010, the go-to place to buy study notes for 14 years now

Start selling
$8.49
  • (0)
  Add to cart